CLINICAL TRIAL: LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS W
CLINICAL TRIAL: LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS W
临床试验：LCCC 0424：I 期厄洛替尼每 72 小时给予患者一次
批准号：
7716826
负责人：
FRANCES COLLICHIO
金额：
$0.11万
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
项目状态：
已结题
起止时间：
2008-04-02 至 2008-05-31
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
This is a research study to investigate a new dosing regimen of erlotinib in patients with glioblastoma multiforme, a type of brain tumor, who have failed first line therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
